Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

Maart 31, 2022
  Gent, België – 31 maart 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (de “Vennootschap” of “Sequana Medical“), een vernieuwer in de behandeling van diuretica-resistente vochtoverbelasting in leveraandoeningen, maligne ascites en hartfalen, zal op donderdag 12 april 2022 haar jaarresultaten per 31 december 2021 bekendmaken. Het managementteam zal een conference call houden met live...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN